Hepatitis delta and HIV infection
Viral liver diseases are frequent comorbidities and major contributors to death in HIV-positive individuals on antiretroviral therapy. Although cure of hepatitis C and control of hepatitis B with antivirals avert liver disease progression in most HIV-coinfected patients, the lack of satisfactory treatment for hepatitis delta virus (HDV) infection remains a major threat for developing cirrhosis and liver cancer in this population. In the European Union (EU) and North America, sexual contact has replaced injection drug use that has been the major transmission route for HDV in HIV-positive persons. PegIFNα is the only approved HDV therapy; however, sustained HDV-RNA clearance is achieved by less than 25%. The recent discovery of sodium taurocholate cotransporting polypeptide as the key hepatitis B virus (HBV) and HDV cell entry receptor has opened the door to a new therapeutic era. Indeed, promising results have been released using Myrcludex-B, a sodium taurocholate cotransporting polypeptide inhibitor. More encouraging are data with new classes of HDV blockers, such as prenylation inhibitors (i.e. lonafarnib) and nucleic acid polymers. At this time, sustained suppression of HDV replication is the primary goal of HDV therapy, as it is associated with normalization of liver enzymes and histological improvement. Of note, the use of specific antivirals for HDV must be given along with anti-HBV agents to prevent HBV rebounds following removal of viral interference. The lack of persistent forms of HDV-RNA could provide a unique opportunity for curing hepatitis delta, even without eliminating HBV circular covalently closed DNA. Ultimately, suppression of HDV replication along with hepatitis B surface antigen clearance once drugs are off would be the best reflect of hepatitis delta cure..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:31 |
|---|---|
| Enthalten in: |
Aids |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Soriano, Vincent [VerfasserIn] |
|---|
| Links: |
|---|
| BKL: |
|---|
| RVK: |
|---|
| doi: |
10.1097/QAD.0000000000001424 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC1993060502 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1993060502 | ||
| 003 | DE-627 | ||
| 005 | 20230512163956.0 | ||
| 007 | tu | ||
| 008 | 170512s2017 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1097/QAD.0000000000001424 |2 doi | |
| 028 | 5 | 2 | |a PQ20170501 |
| 035 | |a (DE-627)OLC1993060502 | ||
| 035 | |a (DE-599)GBVOLC1993060502 | ||
| 035 | |a (PRQ)c1184-236e005a94c1ce251841ff1feb9a0627005b4840b1954fb0a44454e609efd2b50 | ||
| 035 | |a (KEY)0157957620170000031000700875hepatitisdeltaandhivinfection | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 084 | |a XA 16838 |q AVZ |2 rvk | ||
| 084 | |a 44.78 |2 bkl | ||
| 100 | 1 | |a Soriano, Vincent |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hepatitis delta and HIV infection |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a Viral liver diseases are frequent comorbidities and major contributors to death in HIV-positive individuals on antiretroviral therapy. Although cure of hepatitis C and control of hepatitis B with antivirals avert liver disease progression in most HIV-coinfected patients, the lack of satisfactory treatment for hepatitis delta virus (HDV) infection remains a major threat for developing cirrhosis and liver cancer in this population. In the European Union (EU) and North America, sexual contact has replaced injection drug use that has been the major transmission route for HDV in HIV-positive persons. PegIFNα is the only approved HDV therapy; however, sustained HDV-RNA clearance is achieved by less than 25%. The recent discovery of sodium taurocholate cotransporting polypeptide as the key hepatitis B virus (HBV) and HDV cell entry receptor has opened the door to a new therapeutic era. Indeed, promising results have been released using Myrcludex-B, a sodium taurocholate cotransporting polypeptide inhibitor. More encouraging are data with new classes of HDV blockers, such as prenylation inhibitors (i.e. lonafarnib) and nucleic acid polymers. At this time, sustained suppression of HDV replication is the primary goal of HDV therapy, as it is associated with normalization of liver enzymes and histological improvement. Of note, the use of specific antivirals for HDV must be given along with anti-HBV agents to prevent HBV rebounds following removal of viral interference. The lack of persistent forms of HDV-RNA could provide a unique opportunity for curing hepatitis delta, even without eliminating HBV circular covalently closed DNA. Ultimately, suppression of HDV replication along with hepatitis B surface antigen clearance once drugs are off would be the best reflect of hepatitis delta cure. | ||
| 540 | |a Nutzungsrecht: Copyright © 2017 Wolters Kluwer Health, Inc. | ||
| 700 | 1 | |a Sherman, Kenneth E |4 oth | |
| 700 | 1 | |a Barreiro, Pablo |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Aids <London> |d Hagerstown, Md. : Lippincott Williams & Wilkins, 1987 |g 31(2017), 7, Seite 875-884 |w (DE-627)168132583 |w (DE-600)639076-6 |w (DE-576)015929418 |x 0269-9370 |7 nnns |
| 773 | 1 | 8 | |g volume:31 |g year:2017 |g number:7 |g pages:875-884 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1097/QAD.0000000000001424 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_2414 | ||
| 912 | |a GBV_ILN_4125 | ||
| 912 | |a GBV_ILN_4219 | ||
| 936 | r | v | |a XA 16838 |
| 936 | b | k | |a 44.78 |q AVZ |
| 951 | |a AR | ||
| 952 | |d 31 |j 2017 |e 7 |h 875-884 | ||